Prelude Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,401	Closed	-$243K	–	1406
2025 Q2	$243K	Sell	17,401 -50,268	-74%	-$682K	0.02%	712
2025 Q1	$912K	Buy	+67,669	New	+$1.15M	0.07%	332
2024 Q4	–	Sell	-51,050	Closed	-$1.16M	–	1588
2024 Q3	$1.16M	Buy	+51,050	New	+$835K	0.07%	344
2018 Q3	–	Sell	-400	Closed	-$38K	–	2058
2018 Q2	$38K	Buy	400 +67	+20%	+$7.08K	﹤0.01%	1196
2018 Q1	$35K	Buy	333 +66	+25%	+$7.17K	﹤0.01%	1170
2017 Q4	$42K	Sell	267 -166	-38%	-$21.1K	﹤0.01%	970
2017 Q3	$59K	Buy	433 +42	+11%	+$7.06K	0.01%	1049
2017 Q2	$76K	Buy	391 +47	+14%	+$7.93K	0.01%	867
2017 Q1	$64K	Buy	344 +177	+106%	+$30.5K	0.01%	910
2016 Q4	$13K	Buy	+167	New	+$17.4K	﹤0.01%	1357